NCT06357377 - A Study of the Safety, Dosing, and Delivery of NEO100 in Patients with Pediatric Brain Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Pediatric Tumor of CNSPediatric Tumor of BrainDiffuse Midline Glioma, H3 K27M-MutantPediatric Tumor of Brain StemPineocytomaChoroid Plexus Carcinoma, ChildhoodSpinal Cord TumorHigh Grade Glioma

Interventions

DRUG

NEO100

"NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol."